Ligandrol is a novel nonsteroidal oral selective androgen receptor modulator (SARM) currently being investigated in research as a potential treatment for conditions relating to muscle dystrophy and osteoporosis. A recent study has shown that YK11, a selective androgen receptor myostatin inhibitor, accelerates the expression of Follistatin in mice. Follistatin is a myostatin and activin-binding protein naturally found in the human body and has been used as a treatment for several degenerative muscle diseases. When follistatin levels are raised, myostatin levels will be inhibited. Inhibition of myostatin results in increased muscle mass and improved strength.
|Molar Mass||338.253 g·mol−1|
|Molar Mass||430.541 g·mol−1|
|IUPAC Name||methyl (2E)-2-[(8R,9S,10R,13S,14S,17S)-2′-methoxy-2′,13-dimethyl-3-oxospiro[1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-17,5′-1,3-dioxolane]-4′-ylidene]acetate|
|Molar Mass||416.76 g·mol−1|